The efficacy and safety of the SEX BARRIER, bi-hormonal contraceptive drug, for cats, which was used during more than two years (from June 2016 to November 2018), was investigated.
Materials and methods. The doses of preparation and schemes of its applications (to interrupt and to prevent the heat) were used according the instruction.
In the course of entire study we carried out a constant observation of the heat manifestations, periodically (once every two months) ― the complete clinical examination of animals, the ultrasound procedure of reproductive organs, the vaginal cytology, the clinical and biochemical analyses of the blood, and also the level of sex steroids was determined.
Results. Stable suppression of all signs of estrous behavior in cats treated with the drug was observed, which correspond with the vaginal smears and basal levels of estradiol and progesterone in animals throughout the entire study period, which clearly confirms the high efficacy of the drug. The absence of pathological changes in the structure of the ovaries and uterus according to the results of clinical examinations, data of ultrasonography of the pelvic organs, the stability of the main blood parameters, while maintaining their compliance with the physiological norm during the entire study time, and fast (during 3 ... 4 weeks after stopping long-term use of the drug) recovery of the estrous cycle serves as convincing evidence of the safety of long-term use of the bi-hormonal drug for the correction of sexual function in cats.
The article presents the results of monitoring the safety of prolonged use of the oral bihormonal contraceptive drug SEX BARRIER® for delaying and interrupting estrus in home cats by their owners. The use of the bihormonal contraceptive preparation SEX BARRIER® in the home cats by the owners does not lead to disturbances in the genital area, clinical status, morphological and biochemical parameters of animals blood. All owners have confirmed the 100 % effectiveness of the bi-hormonal preparation SEX BARRIER® for both interruption and delay of estrus.
Objective of research: to study the anthelmintic efficacy of the supramolecular complex of
Fenbendazole used against different nematode species in sheep
Materials and methods: Experiments were carried out on young sheep spontaneously
infected with gastrointestinal strongylates (48 head), Dictyocaulus filaria (42 head), Strongyloides
papillosus (21 head) и Trichocephalus ovis (24 head). In each helminthiasis, the supramolecular
complex of Fenbendazole was given once orally to sheep from various groups at the dose of 3,0;
2,0 and 1,0 mg a.i./kg in comparison with the base preparation Fenbendazole at the doses of 1,0
and 3,0 mg/kg. Sheep which didn’t receive the drug served as controls.
The efficacy of drugs was evaluated before and 18 days after dehelmintization according to the
results of coprolarvoscopic examination by flotation and G. Baermann methods. The registration
of drug activity was performed using the «control test».
Results and discussion: Anthelmintic efficacy was studied and a therapeutic dose for the
supramolecular complex of Fenbendazole produced by chemical mechanical technology using
the Drug Delivery System was determined. In gastrointestinal strongylatoses the supramolecular
complex against D. filaria. at the doses of 3,0; 2,0 and 1,0 mg a.i./kg showed the efficacy of 100;
93,4 and 78% , respectively.
The efficacy of supramolecular complex at the dose of 3,0 mg/kg against S. papillosus was
100 %, and against T. ovis - 98,3 % at 10–13% efficacy of the base preparation Fenbendazole at
the dose of 1,0 mg/kg. The therapeutic dose for the supramolecular complex at main nematodiasis
in sheep was 3,0 mg a.i./kg.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.